/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Uromigos
  2. Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC
Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos · Oct 23, 2026

KEYNOTE-905: EV+Pembro boosts EFS/pCR over Pembro alone in cis-ineligible MIBC, but toxicity and adjuvant benefit questions remain.

Pathologic response may plateau after three or four EV cycles

Tom cites EV303 and EV304 as showing similar pathological complete response rates after three versus four neoadjuvant EV cycles. That undercuts the clinical assumption that more neoadjuvant EV necessarily adds benefit, though the transcript gives no direct detail on those trials' designs or patient populations.

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC thumbnail

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos·a month ago

Pembrolizumab alone matches gemcitabine-cisplatin pCR in MIBC

In the ad hoc KEYNOTE-905 analysis, single-agent pembrolizumab produced a 25% pathological complete response, essentially the same as the 27% gemcitabine-cisplatin control rate cited from NIAGARA, despite a high-risk cisplatin-ineligible population. Brian and Tom call this genuine activity, while stressing it is an indirect comparison.

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC thumbnail

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos·a month ago

EV plus pembrolizumab looks additive, not synergistic, in MIBC

Tom reads the hazard ratios as a near-exact stepwise drop: 0.71 for pembrolizumab versus cystectomy and 0.40 for EV plus pembrolizumab, with each component apparently contributing about 0.3. He cautions the 85-patient arms are small, but says the EFS curves visually support this additive pattern.

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC thumbnail

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos·a month ago

Cystectomy alone drives 40-50% grade 3+ events

Anders notes that in the primary KEYNOTE-905 analysis the control arm had grade 3 or higher adverse events in the 40-50% range, likely from surgery alone. That makes the 44% neoadjuvant rate with EV plus pembrolizumab look less alarming than a simple cross-arm comparison might suggest.

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC thumbnail

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos·a month ago

KEYNOTE-905 cannot answer how much adjuvant therapy is needed

Tom points out that all patients received a year of adjuvant therapy in the experimental arms, but only about 25% of the ITT population completed all nine EV cycles, and little is known about who they were. The three-arm ad hoc analysis therefore cannot isolate the adjuvant phase's benefit or necessity.

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC thumbnail

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos·a month ago

No perioperative single-agent pembrolizumab niche exists

Tom argues that if a patient is fit enough for cystectomy, they should be fit enough to start EV plus pembrolizumab, so the single-agent perioperative pembrolizumab scenario is mostly hypothetical in his view. The exception he describes is metastatic lymph-node-only disease with comorbidities, not curative-intent MIBC.

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC thumbnail

Episode 522: ESMO 2026 - KEYNOTE-905 Analysis of Neoadjuvant EVP or Pembro Monotherapy in Cis-ineligible MIBC

The Uromigos·a month ago